OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.

挪威奥斯陆和波士顿--（商业新闻短讯）--临床阶段生物技术公司Calluna Pharma AS（Calluna）今天宣布任命Mark Gaffney为首席执行官，Mark Altmeyer为董事会主席，Calluna Pharma AS（Calluna）是治疗炎症和纤维化疾病的一流抗体的先驱。

Alongside these appointments, John Montana, who has been acting as the Company's interim CEO, will return to his role as an Operating Partner at Forbion..

除了这些任命之外，一直担任公司临时首席执行官的约翰·蒙塔纳（JohnMontana）将重返福比昂（Forbion）的运营合伙人岗位。。

Gaffney brings over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, and will lead the team that defines and executes on the corporate strategy, particularly as its lead program is on pace to complete its Phase 1 program later this year.

加夫尼在私营和公共生物技术公司的企业战略、业务发展和运营方面拥有20多年的经验，并将领导定义和执行企业战略的团队，特别是因为其领导计划正在加快完成今年晚些时候的第一阶段计划。

Prior to Calluna, Gaffney was CEO of Oxular Limited, a company developing novel drug delivery and formulation technologies to treat retinal disorders, where he remains a strategic advisor and member of the Board. Before joining Oxular, he served as Chief Business Officer and later as Chief Operating Officer at Vedere Bio, a company focused on developing next-generation ocular gene therapies, which was acquired by Novartis in late 2020.

在Calluna之前，Gaffney是Oxular Limited的首席执行官，Oxular Limited是一家开发新型药物输送和配方技术以治疗视网膜疾病的公司，他仍然是该公司的战略顾问和董事会成员。在加入Oxular之前，他曾担任Vedere Bio的首席商务官，后来担任首席运营官。Vedere Bio是一家专注于开发下一代眼部基因疗法的公司，于2020年底被诺华收购。

Gaffney has held corporate development and operational positions at Cyclerion Therapeutics and Ironwood Pharmaceuticals and holds a degree in engineering from the University of Pennsylvania and a Juris Doctor degree from Boston University..

Gaffney曾在Cyclerion Therapeutics和Ironwood Pharmaceuticals担任公司开发和运营职位，并拥有宾夕法尼亚大学工程学位和波士顿大学法学博士学位。。

Altmeyer, the newly appointed Independent Chair of the Calluna Board, brings extensive leadership experience, having served on the boards and as an advisor to several pharma and biotech companies. He is currently Chair of AM-Pharma and also serves on the boards of Novaremed, Merz Therapeutics, Aculys, and Alector, all focusing on CNS and neurological treatments.

新任命的Calluna董事会独立主席Altmeyer拥有丰富的领导经验，曾在董事会任职，并担任多家制药和生物技术公司的顾问。他目前是AM Pharma的主席，还担任Novaremed，Merz Therapeutics，Aculys和Alector的董事会成员，所有董事都专注于中枢神经系统和神经系统治疗。

Previously, he was President and CEO of Arvelle Therapeutics, Chief Commercial Officer at Axovant Sciences, and held senior roles at Otsuka America and Bristol-Myers Squibb. Altmeyer holds a BA in Economics from Middlebury College and an MBA from Harvard Business School..

此前，他曾任Arvelle Therapeutics总裁兼首席执行官，Axovant Sciences首席商务官，并在大冢美国和百时美施贵宝担任高级职务。Altmeyer拥有米德尔伯里学院经济学学士学位和哈佛商学院工商管理硕士学位。。

Mark Gaffney, Chief Executive Officer of Calluna Pharma, said: “It has been a rapid and impressive start to our journey as Calluna Pharma following joining forces of Oxitope Pharma and Arxx Therapeutics, two key players in the innate immunology space. I am delighted to join the team at such an exciting stage with Calluna’s lead candidate, CAL101, completing its Phase 1 program this year, and with the other programs in our pipeline demonstrating such promise.

Calluna Pharma首席执行官马克·加夫尼（Mark Gaffney）表示：“在Oxitope Pharma和Arxx Therapeutics（先天免疫学领域的两个关键参与者）联手之后，我们作为Calluna Pharma的旅程有了一个快速而令人印象深刻的开始。我很高兴在如此激动人心的阶段加入团队，Calluna的主要候选人CAL101今年完成了第一阶段的计划，我们正在筹备的其他计划也证明了这一承诺。

I look forward to working with Mark Altmeyer, the other members of our Board and the team as we continue to progress Calluna’s programs to make treatments for fibrotic and inflammatory diseases a reality.”.

我期待着与Mark Altmeyer、董事会其他成员和团队合作，继续推进Calluna的计划，使纤维化和炎症性疾病的治疗成为现实。”。

Mark Altmeyer, Chair of the Board of Calluna Pharma, commented: “It’s a great time to be joining Calluna Pharma’s Board and I look forward to working with Mark Gaffney as we steer company growth and the development of our programs. Working closely with Mark and his leadership team, we will continue to advance our mission to target the root causes of inflammation and fibrosis.”.

Calluna Pharma董事会主席Mark Altmeyer评论道：“现在是加入Calluna Pharma董事会的好时机，我期待着与Mark Gaffney合作，指导公司的成长和项目的发展。与Mark及其领导团队密切合作，我们将继续推进我们的使命，以解决炎症和纤维化的根本原因。”。

Marco Boorsma, General Partner, Forbion, outgoing Chair and member of the Board of Calluna Pharma, added: “Calluna’s tailored approach to targeting the root causes of many diseases can be successful where other treatment strategies have fallen short. The Company and its pipeline are poised for success, and I feel confident as we hand over the Chairmanship to Mark Altmeyer who brings vast experience for the next phase of this journey.

即将离任的Calluna Pharma董事长兼董事会成员Forbion的普通合伙人Marco Boorsma补充道：“Calluna针对许多疾病的根本原因量身定制的方法在其他治疗策略不足的情况下可能会取得成功。该公司及其管道正准备取得成功，当我们将主席职位移交给Mark Altmeyer时，我感到很有信心，他为这段旅程的下一阶段带来了丰富的经验。

I would also like to thank John Montana for his leadership and dedication in building the strong foundations for the Company and to welcome Mark Gaffney as incoming CEO.”.

我还要感谢约翰·蒙塔纳（JohnMontana）在为公司奠定坚实基础方面的领导才能和献身精神，并欢迎马克·加夫尼（MarkGaffney）出任新任首席执行官。”。